|
Oct.
17, 2001 (Frankfort, Ky.) -- Gov.
Paul Patton today handed out $3.8 million of Tobacco
Settlement money to 20 researchers from the University
of Kentucky and University of Louisville for lung
cancer research.
The grants
are part of the Lung Cancer Research Project that
Governor Patton and lawmakers created in the 2000
General Assembly to combined efforts of UK and U of
L to become national leaders in lung cancer basic
research, early detection, diagnosis and treatment.
"Lung cancer
is a significant problem in Kentucky. About 3,000
Kentuckians die each year from it. This type of cancer
kills more Kentuckians annually than breast, colon,
pancreas and prostate cancers combined," Patton said.
"These figures are staggering and make the mission
and importance of our universities' research even
greater."
The Lung
Cancer Research Project is a 20-year initiative that
was designed to receive 20 percent of all moneys in
the Tobacco Master Settlement Agreement for this collaborative
partnership between the two universities. The project's
nine-member board helped select the 20 grant recipients
from a total of 54 initial requests.
Dr. Donald
Miller, director of the James Graham Brown Cancer
Center at the University of Louisville, and Dr. Alfred
Cohen, director of the Markey Cancer Center at the
University of Kentucky, will help oversee the direction
of the 20 grants, which were funded for two years.
"This
amount of funding is going to help the researchers
change the face of how our universities and medical
centers deal with lung cancer and help provide us
with critical information in this fight," Patton said.
The researchers
who received grants include:
Name/University
Research
Mansoor
Ahmed: UK, TGF-beta signaling and radiation response
in lung carcinoma
Douglas
A. Andres: UK, Novel ras-related GTPase in lung cancer
Paula J.
Bates: U of L, Nucleolin: A novel marker and therapeutic
target for lung cancer
Haribabu
Bodduluri: U of L, Role of G-protein coupled receptor
mediated motility in lung cancer
Stephen
A. Brown: UK, Radioprotective agents in NSCLC therapy
John W.
Eaton: U of L, Pro-inflammatory and clastogenic actions
of smoke-borne free fatty acids
H. Leighton
Grimes: U of L, Involvement of the GF11 oncoprotein
in human lung cancer
Ramesh
C. Gupta: UK, Etiology and prevention of lung cancer:
Biomarker development in clinical studies
David A.
Hein: U of L, Environmental genomics and molecular
epidemiology of lung cancer: Functional characterization
of N-acetyltransferase-1 and -2 genetic polymorphisms
Louis B.
Hersh: UK, A gene therapeutic approach for the treatment
of lung cancer
Edward
Hirschowitz: UK, Therapeutic investigation of dendritic
cell vaccines in NSCLC
Glenn McGregor:
U of L, Mechanisms of BPDE-induced mutagenesis and
mutation avoidance
Marcos
A. Oliveira: UK, A novel chemo-radio sensitizing target:
PARP-2 activation domain
Stephen
C. Peiper: U of L, Role of G-protein coupled receptors
in lung cancer biology: Novel approaches to block
proliferation and spread
Gordon
D. Ross: U of L, Oral adjuvant immunotherapy of lung
carcinoma
William
St. Clair: UK, Novel anticancer agents to promote
the efficacy of contemporary or GRID radiation therapy
for treatment of lung cancer
Sandra
Sephton: U of L, Psychosocial effects in lung cancer
outcomes
Haval Shirwan:
U of L, A novel approach to tumor vaccination
H. Peter
Spielman: UK, Pre-clinical studies of novel ras function
inhibitors to treat lung cancer
John R.
Yannelli: UK, Use of dendritic cells to present non-small
cell lung cancer associated antigens
|
